Skip to Main Content

Scientist Jim Wilson is synonymous with gene therapy — and for good reason.

For decades, the celebrated researcher has been a pioneer in the field, focused on the development of treatments for rare, often overlooked diseases. His work has generated millions of dollars for his employer, the University of Pennsylvania, and made Wilson a towering figure in the gene therapy world, with the wealth and fame to match.

advertisement

But a STAT investigation reveals Wilson’s success has obscured a darker side to his leadership of the Gene Therapy Program, the acclaimed university research center he runs — a style that for years permitted toxicity and mismanagement to roil the workflow of lab experiments and research inside the program’s facilities on the leafy Philadelphia campus.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.